Pro: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?

Medicine & Life Sciences

• Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 100%
• Rituximab 75%
• Microscopic Polyangiitis 25%
• Compliance 23%
• Antineutrophil Cytoplasmic Antibodies 21%
• Granulomatosis with Polyangiitis 21%
• Fertility 16%
• Cyclophosphamide 16%
• Health Care Costs 15%
• Remission Induction 11%
• Insurance Carriers 11%
• Azathioprine 9%
• Patient Preference 9%
• Decision Making 7%
• Data Analysis 6%
• Randomized Controlled Trials 5%
• Costs and Cost Analysis 5%
• Safety 5%
• Recurrence 4%
• Kidney 4%
• Pharmaceutical Preparations 3%
• Neoplasms 2%
• Therapeutics 1%